Dear Molecular Imaging Insider,
The world of molecular imaging is constantly full of new discoveries, and this issue of the Molecular Imaging Insider is no exception.
Evidence supporting the value of PET/MRI continues to mount: In a pilot study from Germany, researchers found that the hybrid imaging modality is effective for assessing large-vessel vasculitis. Get all of the details in this issue's Insider Exclusive, available to you first as an Insider subscriber.
Researchers at NYU Langone Medical Center have also added evidence to the possible connection between sleep disorders and Alzheimer's disease. In a study presented at last month's Alzheimer's Association International Conference in Copenhagen, they used PET with FDG and Pittsburgh Compound B to show the correlation among cognitively normal elderly patients.
Meanwhile, researchers from Thomas Jefferson University have found that using PET brain imaging with florbetapir and FDG can differentiate cardiovascular disease from symptoms of mild cognitive impairment or Alzheimer's disease.
Have you ever heard of radiomics? If not, read our article on how extracting statistical information and other measurements from PET images can help determine an accurate dose of radiation therapy. The technique is considerably different from simply identifying the presence of cancer or outlining the extent of disease to target radiation dose.
Finally, a team from the University of Wisconsin's UW Health system has completed the first successful human clinical trial of a new PET radiopharmaceutical that targets and detects brain tumors more specifically than FDG. Iodine-124 CLR1404 is designed to enter cells through membrane lipid rafts, which are overexpressed in cancer cells and serve as a platform for cell proliferation.
Be sure to stay in touch with the Molecular Imaging Digital Community on a daily basis to learn about the latest news and research.
